Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancerF Mosele, B Stefanovska, A Lusque, et al.
ESMO Open|June 4, 2026
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trialC Blaye, F-C Bidard, L Hue, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2014
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signatureC A Drukker, H C van den Hout, G S Sonke, et al.
ESMO Open|June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-BF Marmé, M Martin, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2025
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-BS Loibl, M Martin, H Bonnefoi, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017G Curigliano, H J Burstein, E P Winer, et al.
Pageof 5